News
-
Investigational Cis-urocanic Acid Eye Drops For Dry Eye Syndrome Well Tolerated, In Phase 1 Clinical Study
6/28/2012
Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to investigate the tolerability and safety of the ophthalmic product as well as pharmacokinetics after single and repeated dosing.
-
Boston Therapeutics Completes Enrollment In Phase ll Clinical Trial To Evaluate PAZ320 In Patients With Type 2 Diabetes
6/22/2012
Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "The Company"), a developer of complex carbohydrates to treat diabetes and inflammatory diseases, today announced it has completed enrollment in a Phase ll clinical trial to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with Type 2 diabetes at Dartmouth-Hitchcock Medical Center in Lebanon, NH. PAZ320 is a non-systemic chewable tablet designed to reduce post-meal elevation of blood glucose.
-
Abbott Presents Results Of Clinical Studies Evaluating Its Investigational Treatment For Advanced Parkinson's Disease
6/18/2012
Today Abbott (NYSE: ABT) announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease. The abstracts include the results from the second interim analysis of a long-term safety and tolerability trial, as well as secondary endpoint analyses from the Phase 3 pivotal trial.
-
Computer Model Successfully Predicts Drug Side Effects
6/11/2012
A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature. By Kristen Bole
-
Abbott Announces Initiation Of Phase 3 Study Of Elagolix In Patients With Endometriosis
6/5/2012
Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist.
-
Phase III Study: Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy
6/4/2012
Final results from PARAMOUNT, a Phase III study of ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company (NYSE: LLY).
-
Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival
5/22/2012
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
-
Children With Cancer Have Complete Responses In A Children’s Oncology Group Phase 1 Trial
5/16/2012
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
-
New Laboratory Technique Captures microRNA Targets
5/9/2012
Human cells are thought to produce thousands of different microRNAs (miRNAs)—small pieces of genetic material that help determine which genes are turned on or off at a given time.
-
Quanticate Selects Comprehend Clinical Data Visualization And Analytics Platform
5/3/2012
While clinical development technologies have come a long way in recent years, research sponsors continue to struggle to connect disparate systems and attain easy access to critical data that will enable better reporting, faster problem solving and increased operational efficiencies.